News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Smoker's Cough Treatment Beats GlaxoSmithKline (GSK)'s Advair in Trial



8/29/2012 7:29:15 AM

Patients taking Novartis AG (NOVN)’s experimental once-daily treatment for smoker’s cough showed a significant improvement in lung function over those on an existing medicine marketed by GlaxoSmithKline Plc (GSK), which is also developing a successor drug. Patients taking Novartis’s QVA149 were able to expel 100 milliliters (3.4 ounces) more air from their lungs in one second than those receiving Glaxo’s best-selling Advair after 26 weeks of treatment, according to a summary of data from a trial dubbed “Illuminate” to be presented at the European Respiratory Society annual meeting next week.

Read at BusinessWeek


comments powered by Disqus
   
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES